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In  anemic  patients  receiving  myelosuppressive  chemotherapy,  erythropoiesis-stimulating  agents  (ESAs)
raise hemoglobin  levels  and  reduce  transfusion  requirements,  but  ESA-related  safety  concerns  exist.  To
evaluate ESA  beneﬁts  and  risks  in  lung  cancer,  we  conducted  meta-analyses  of  data  from  controlled  ESA
trials  conducted  in  lung  cancer  patients.  Study-level  analyses  included  controlled  ESA trials  reporting
lung  cancer  mortality,  identiﬁed  from  the  2006  Cochrane  ESA  report  and  from  a  systematic  search  for
studies  published  through  December  2010.  Patient-level  analyses  included  data  from  lung  cancer  patients
receiving  chemotherapy  in  Amgen  studies  evaluating  darbepoetin  alfa  (DA)  vs  placebo.  Study-level  and
patient-level  analyses  examined  deaths,  progression,  and  transfusion  incidence.  Patient-level  analyses
also  examined  adverse  events  (AEs)  and  fatigue.
In  a study-level  meta-analysis  of  nine  ESA  studies  of 2342  patients  receiving  chemotherapy,  the  ESA
odds ratio  (OR)  was  0.87  (95%  conﬁdence  interval  [CI]  0.69–1.09)  for  mortality;  the  overall  random-effects
risk  difference  (95%  CI)  for  mortality  was  −0.02  (−0.06,  0.02).  The  ESA  OR  (95%  CI) for  disease  progression
in  ﬁve  chemotherapy  studies  reporting  progression  was  0.84  (0.65–1.09).  The  ESA odds  ratio  (95%  CI)
was  0.34  (0.28–0.41)  for  transfusion  incidence.
In  a  patient-level  meta-analysis  of four  studies  evaluating  1009 patients  through  follow-up,  the median
survival  time  was  41  weeks  with  DA  and  38  weeks  with  placebo.  During  the  combined  study  and  follow-
up  periods,  80%  of  placebo-group  patients  and  74% of DA patients  died  (mortality  hazard  ratio  [HR]
0.90  [95%  CI,  0.78–1.03]  for DA);  results  were  similar  for  small  cell  lung  cancer  and  non-small  cell  lung
cancer.  Overall,  87%  of  placebo  patients  and  84%  of  DA  patients  progressed  or  died.  Fewer  DA patients
had  transfusions  (week  5 through  end-of-study,  DA 19%,  placebo  43%).  AEs included  thrombotic/embolic
events  (DA  10.5%,  placebo  7.2%),  cerebrovascular  disorders  (DA  3.7%,  placebo  4.2%),  pulmonary  edema
(DA 0.4%,  placebo  1.0%)  and  pulmonary  embolism  (DA  1.8%,  placebo  0.6%).
These  meta-analyses  suggest  that  ESAs  reduce  transfusions  without  increasing  mortality  or  disease
r  patprogression  in  lung  cance
. IntroductionAnemia is common in lung cancer patients receiving myelosup-
ressive chemotherapy [1],  potentially causing fatigue, dyspnea,
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© 2012 Elsevier Ireland Ltd. 
depression, and other co-morbidities and increasing costs and
caregivers’ time burdens [1–4]. The estimated incidence of ane-
mia  in lung cancer patients undergoing chemotherapy ranges
from 50% to 86%, increasing over the course of treatment [1,4,5]
and occurring commonly in patients receiving platinum-based
regimens [6]. Treatments for anemia associated with myelosup-
Open access under CC BY-NC-ND license.pressive chemotherapy include red blood cell (RBC) transfusions
and erythropoiesis-stimulating agents (ESAs). Transfusions reverse
anemia quickly, but this effect is often transient. Transfusions also
expose patients to risks including transmission of infectious agents,
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ransfusion-related acute lung injury, iron overload, and hemolytic
eactions [7,8]. ESAs, which stimulate the production of RBCs, are
pproved in the United States and European Union for treating ane-
ia  associated with chemotherapy [9–13]. Randomized, controlled
rials in lung cancer [14,15] and other nonmyelogenous tumor
ypes [16–18] have shown that ESAs can increase hemoglobin levels
nd reduce transfusion requirements and patient-reported fatigue
n patients receiving chemotherapy [15,17,19,20].  However, evi-
ence also suggests that ESAs may  increase the risk for thrombotic
nd embolic events [21,22]. Because lung cancer patients receiving
hemotherapy commonly develop anemia, understanding the risks
nd beneﬁts associated with ESA use in this patient population may
elp to optimize lung cancer care.
The possibility has been discussed that ESA use may  increase
ortality, disease progression, or both in oncology patients.
hough an increased risk for thrombotic and embolic events with
SA use is well characterized and described in the ESA-label prod-
ct information [9–13], results from controlled ESA oncology trials
nd from meta-analyses of these trials regarding the effect of
SAs on disease progression and mortality have been inconsis-
ent [23–25].  In response to ESA safety issues, ESA product labeling
as changed to include information on eight clinical trials of con-
ern, which reported an association between ESA use and increased
ortality and/or disease progression [9,11–13,26]. These trials
ere conducted in various cancer types and oncology settings
ncluding the indicated chemotherapy setting [16,27–30],  and the
on-indicated settings of treatment with radiotherapy only [31,32]
r no treatment with chemotherapy or radiotherapy (anemia of
ancer) [33,34]. One trial (EPO-CAN-20) reporting an association
etween ESA use and increased mortality was conducted in non-
mall cell lung cancer (NSCLC) patients not receiving chemotherapy
r radiotherapy [34]. To date, no other controlled ESA trials in
ung cancer patients have reported safety signals regarding ESA-
ssociated survival and disease progression [24], suggesting a need
o examine the total body of evidence regarding how ESAs affect
utcomes in lung cancer.
Ten controlled studies examining ESA efﬁcacy and safety in
ung cancer have reported mortality data to date, although sur-
ival was not the primary endpoint in most [14,15,34–41]. Nine
tudies were conducted in the chemotherapy setting, and one
34] in patients with cancer not receiving chemotherapy or radio-
herapy. To systematically evaluate the risks and beneﬁts of ESA
herapy for patients with small cell lung cancer (SCLC) or NSCLC and
dentify factors that might predict survival, we conducted meta-
nalyses of these controlled ESA lung cancer studies. These analyses
ncluded study-level data from controlled trials of various ESAs
14,15,34–41] and pooled patient-level data from controlled darbe-
oetin alfa (DA) trials [14,15,42,43].  Outcomes examined included
SA effects on mortality, disease progression, and transfusion inci-
ence. The patient-level meta-analyses also examined the impact
f DA use on the incidence of adverse events (AEs) and patient-
eported fatigue and whether baseline factors predicted reduced
urvival outcomes.
. Methods
.1. Study-level meta-analysis
Studies for the study-level meta-analysis were identiﬁed using
he 2006 Cochrane Collaborative report (Analysis 05.05) [21] as the
tarting point. We  also conducted a systematic literature review
f ESA studies in lung cancer published from April 2005 to August
010 and described in relevant abstracts and associated poster
resentations delivered from 1995 through 2010 at conferences
f the American Society of Clinical Oncology, American Societyncer 76 (2012) 478– 485 479
of Hematology, and the European Society for Medical Oncology.
Included studies were randomized, controlled trials of lung cancer
patients treated with epoetin alfa, epoetin beta, or DA plus transfu-
sions compared with control patients who received placebo or best
standard of care or prophylaxis (e.g., transfusions without ESAs)
for treatment of anemia; studies had to report mortality data. For
studies conducted by Amgen and Janssen Products, LP (formerly
Ortho Biotech Products, LP), analyses included current data from
internal databases for randomized, controlled ESA trials that met
the search criteria. Data for epoetin beta studies were collected
from publications only. See the Online Supplementary Appendix
for more details about the literature search and study selection.
Endpoints were deaths, progression-related outcomes, and the
incidence of transfusion. Analysis of the incidence of thrombotic
and embolic events was  deemed not feasible because of inconsis-
tent deﬁnitions across studies.
Data were summarized using Comprehensive Meta-Analysis
Software (V2). In one study [38], patients randomly assigned into
different ESA dose groups were analyzed as a single ESA group. In
another study [15], SCLC and NSCLC patient data were analyzed sep-
arately, but combined for the meta-analysis of all patients. Analyses
were on an intent-to-treat basis whenever possible for consis-
tency with direction from the US Food and Drug Administration.
This method differs from that of some published studies, which
describe death as a safety endpoint, analyzed by the treatment
received. The primary analysis used odds ratios (ORs) to compare
results for the ESA-treated patients to control patients. To con-
ﬁrm these results for the analysis of deaths, a sensitivity analysis
was  also performed using the risk difference (the difference in the
actual percentage of deaths) rather than the odds ratio (the relative
comparison of deaths). The analyses used a random-effects model
because of known differences in the designs of included studies.
Heterogeneity, if found, was  reported using the I2 statistic [44].
2.2. Patient-level meta-analysis
Lung cancer patients were identiﬁed in all Amgen-sponsored
randomized, placebo-controlled trials in the setting of anemia in
patients receiving chemotherapy. Of four DA studies identiﬁed,
two  included only lung cancer patients and two others included
lung cancer patients and patients with other tumor types. The
meta-analysis included both published and unpublished results.
Lung cancer patients included in this analysis were a subset of the
patients in the meta-analysis reported by Ludwig et al. [45].
Endpoints were deaths, progression-free survival, AEs of
interest including thrombotic and embolic events and respiratory-
speciﬁc AEs, RBC transfusion incidence from week 1 or week 5
to the end of study, and fatigue as reported on the Functional
Assessment of Cancer Therapy-Fatigue (FACT-F) tool. Most end-
points were analyzed separately for SCLC and NSCLC and for all lung
cancers combined. Disease progression was analyzed as reported,
although methods of assessing disease progression varied among
studies. Analyses also evaluated whether baseline factors could
predict survival in ESA-treated lung cancer patients; see the Online
Supplementary Appendix.
The patient-level analysis was performed using SAS V9.1 soft-
ware. All endpoints were reported by randomized treatment
groups. In the Kotasek study [43], the different DA dose groups
were analyzed as a single DA group; because patients randomly
assigned to placebo could cross over to DA after 12 weeks, data were
truncated at the end of the double-blind treatment period. Hazard
ratios (HRs) were generated to summarize the effect of DA rela-
tive to placebo for time-to-event endpoints (overall survival and
progression-free survival) using Cox proportional hazards models
stratiﬁed by study. The median time to events was  estimated using
the Kaplan–Meier method with 95% conﬁdence intervals (CIs);
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urvival curves for overall survival and progression-free survival
ere generated. AEs of interest for this patient population were
dentiﬁed based on standard medical queries using Medical Dic-
ionary for Regulatory Activities (MedDRA) V12.1, updated from
edDRA V9.0, which was used for the meta-analysis reported in
udwig et al. [45]. Mean (SD) change in FACT-F scores and crude per-
entages of patients who had AEs of interest were also generated.
. Results
.1. Study-level meta-analysis
The ten studies in the study-level meta-analysis evaluated
412 lung cancer patients (ESA 1227, control 1185; Table 1)
14,15,34–41]. Data from the Vansteenkiste study were analyzed
eparately for patients with SCLC and NSCLC and for all patients.
ine studies (N = 2342; ESA 1194, control 1148) were conducted in
he chemotherapy setting. The EPO-CAN-20 study [34], conducted
n patients not receiving chemotherapy or radiotherapy, was halted
ecause of excess mortality in the ESA group after enrollment of 70
f the planned 300 patients. Only one study [14] enrolled patients
tarting their ﬁrst cycle of platinum and etoposide chemotherapy
ith survival as an efﬁcacy endpoint.
When the nine trials in which patients received chemother-
py were meta-analyzed for mortality (Fig. 1A), the ESA odds ratio
OR) for death was 0.87 (95% CI, 0.69–1.09, random effects model).
esults were similar for patients with SCLC and NSCLC (Fig. 1A).
he I2 showed moderate heterogeneity among the studies: 16% for
ll lung cancer patients receiving chemotherapy; 11% for SCLC; and
8% for NSCLC. The risk difference sensitivity analysis for mortality
howed a consistent result, with an overall random-effects risk dif-
erence (95% CI) of −0.02 (−0.06, 0.02) and an I2 of 21% (Fig. 1B). For
he one study conducted in patients not receiving chemotherapy or
adiotherapy [34], the mortality OR was 2.82 (95% Cl, 0.28–28.56);
he risk difference was 0.05 (−0.06, 0.16). The OR for disease pro-
ression in the study-level analysis was estimated to be 0.84 (95%
I, 0.65–1.09) for the ﬁve chemotherapy studies with disease pro-
ression data (Fig. 1C).
able 1
tudies Included in meta-analyses.
Study number or alias Treatment Control group Study-level
analysis
Pat
an
EPO-CAN-20 None Placebo a
EPO-GER-22 Chemotherapy,
radiotherapy
No ESA  
EPO-INT-49 Chemotherapy Placebo  
EPO-CAN-15 Chemotherapy,
radiotherapy
Placebo  
CC2574-P-169 Chemotherapy No ESA  
N93-004 Chemotherapy Placebo  
DE-2004-007 Chemotherapy No ESA  
EPO-GER-20 Chemotherapy No ESA  
AMG  20010145 Chemotherapy Placebo   
AMG  980297 Chemotherapy Placebo   
AMG  20030232 Chemotherapy Placebo  
AMG  980291 Chemotherapy Placebo  
CLC: small cell lung cancer; NSCLC: non-small cell lung cancer; and ESA: erythropoiesis-
a A diamond indicates that a study was included in the meta-analysis.
b The 2008 abstract by Nagel et al. was used for this analysis; the data have since been
chuette W.  Addition of darbepoetin alfa to dose-dense chemotherapy: results from a ran
toposide. Clin Lung Cancer 2011;12:62–9.
c Based on data provided in the Cochrane Collaborative report for the meta-analysis o
vailable.
d In this study, 600 patients were randomized. A total of 596 patients (298 per treatme
resented in Pirker (2008, Table 1); 597 (299 darbepoetin alfa; 298 placebo) patients w
atient-level analysis, Pirker (2008, Fig. 1).
e Only lung cancer patients were analyzed from these studies of patients with multip
ecause data speciﬁc to those patients with lung cancer were not reported in the publicancer 76 (2012) 478– 485
In the eight studies in lung cancer patients receiving chemother-
apy that reported transfusion data, the OR for transfusion was 0.34
(95% CI, 0.28–0.41) (Fig. 1D); the transfusion incidence was gen-
erally lower with ESAs than with controls. The EPO-CAN-20 study
[34] was excluded from this analysis because it was conducted in a
non-indicated setting.
3.2. Patient-level meta-analysis
The patient-level meta-analysis included data from four DA
studies (1009 patients; DA 512, placebo 497) [14,15,42,43].  Of these
patients, 714 had SCLC (DA 363, placebo 351) and 295 had NSCLC
(DA 149, placebo 146). Baseline demographics and disease char-
acteristics were similar between groups (data not shown). Most
patients were European or Australian (90%); 99% were Caucasians,
and 66% were men. The median age was 62 years; 38% of patients
were >65 years of age. Most patients (95%) had stage III or IV dis-
ease; 78% had an ECOG performance status of 0 or 1.
Among all lung cancer patients, the median survival time was
41 weeks with DA and 38 weeks with placebo (Fig. 2A). In both
groups, 15% of patients died on study (HR 1.02; 95% CI, 0.74–1.40)
(Table 2). During the combined study and follow-up periods, 80% of
placebo-group patients and 74% of DA patients died (HR 0.90; 95%
CI, 0.78–1.03) (Table 2). Results were similar for SCLC and NSCLC
(Table 2, Fig. 2A).
Rates of disease progression or death and Kaplan–Meier esti-
mates of progression-free survival time were similar between
treatment groups, both on study and during the combined on-study
and follow-up periods. Median progression-free survival time was
shorter for NSCLC than for SCLC (Table 2, Fig. 2B), but interpretation
of disease progression data was  complicated by the fact that only
the Pirker study of SCLC patients [14] assessed tumor progression
using blinded centralized radiographic review.
Transfusions were approximately half as frequent in the DA
group as in the placebo group among all lung cancer patients across
all studies (week 5 through end of study) (Fig. 2C). Mean base-
line FACT-F scores (range 0–52; higher scores indicate less fatigue)
were approximately 30 for both treatment groups for all patients
ient-level
alysis
SCLC (number
of patients)
NSCLC (number
of patients)
Reference
70 Wright et al. [34]
385 Debus et al. [39]
424 Milroy et al. [40]
104 Goss et al. [35]
130 Thatcher et al. [38]
224 Grote et al. [36]
72 Nagel et al.b [37]
93 Bohlius et al.c [41]
596/597d Pirker et al. [14]
92 222 Vansteenkiste et al. [15]
15 40e Hernandez et al. [42]
10 33e Kotasek et al. [43]
stimulating agent.
 published as Nagel S, Kellner O, Engel-Reidel W,  Guetz S, Schumann C, Gieseler F,
domized phase II trial in small-cell lung cancer patients receiving carboplatin plus
f individual patient data (reported as study 31678); primary publication was not
nt arm) were analyzed in the study-level analysis per the planned efﬁcacy analysis
ho  received at least one dose of study drug were analyzed as randomized in the
le tumor types; these studies were not included in the study-level meta-analysis
tions.
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C),  and incidence of transfusion (D). CI: conﬁdence interval; NSCLC: non-small ce
eterogeneity statistic; and SE: standard error.
nd subgroups. Patients in the overall lung cancer population
xperienced a greater mean [SD] improvement in FACT-F scores
rom baseline with DA than with placebo (1.31 [11.10] vs 0.44
11.67]). Among SCLC patients, patients in both treatment groups
xperienced an improvement in mean [SD] FACT-F scores from
aseline (DA 1.69 [11.40], placebo 1.31 [11.97]). Among patients
ith NSCLC, the mean (SD) improvement in FACT-F scores from
able 2
ummary of deaths and progression-free survival: patient-level meta-analysis.
Deaths All lung cancers 
Darbepoetin alfa Plac
Number of on-study deaths (%) 78 (15) 75
On-study death HR (95% CI) 1.02 (0.74–1.40) 
Overall  number of deaths including follow-up, n (%) 377 (74) 398
Overall deaths including follow-up HR (95% CI) 0.90 (0.78–1.03) 
PFS  on-study, n (%)a 227 (44) 206
On-study PFS HR (95% CI)a 1.06 (0.88–1.28)
PFS  including follow-up, n (%)a 430 (84) 433
PFS  including follow-up HR (95% CI)a 0.92 (0.81–1.06) 
SCLC: non-small cell lung cancer; SCLC: small cell lung cancer; HR: hazard ratio; CI: con
a Number of surviving patients without disease progression.is-stimulating agents (ESA) vs control on mortality (A and B), disease progression
g cancer; SCLC: small cell lung cancer; ESA: erythropoiesis-stimulating agent; I2:
baseline was  0.54 (10.46) with DA, whereas patients in the placebo
group experienced a mean (SD) worsening in fatigue of −1.45
(10.81) points.Among all lung cancer patients, a higher percentage of patients
reported an AE of interest with DA than with placebo (27.0% vs
22.9%) (Table 3). This difference was primarily due to differences
in rates of thrombotic and embolic events (DA, 10.5%; placebo,
NSCLC SCLC
ebo Darbepoetin alfa Placebo Darbepoetin alfa Placebo
 (15) 21 (14) 19 (13) 57 (16) 56 (16)
1.12 (0.60–2.09) 0.99 (0.69–1.44)
 (80) 75 (50) 87 (60) 302 (83) 311 (89)
0.84 (0.62–1.15) 0.91 (0.78–1.07)
 (41) 62 (42) 61 (42) 165 (45) 145 (41)
0.92 (0.64–1.32) 1.13 (0.90–1.41)
 (87) 110 (74) 117 (80) 320 (88) 316 (90)
0.89 (0.68–1.15) 0.95 (0.81–1.11)
ﬁdence interval; and PFS: progression-free survival.
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Fig. 2. Patient-level meta-analyses of effects of darbepoetin alfa vs placebo on mortality (A), disease progression (B), and transfusion rates (C) in lung cancer patients receiving
chemotherapy. CI: conﬁdence interval.
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Table 3
Number of patients reporting adverse events of interest: patient-level meta-analysis.
Event All lung cancers NSCLC SCLC
Darbepoetin
alfa N = 512
Placebo N = 497 Darbepoetin
alfa N = 149
Placebo N = 146 Darbepoetin
alfa N = 363
Placebo N = 351
Adverse events of interesta, n (%) 138 (27.0) 114 (22.9) 44 (29.5) 36 (24.7) 94 (25.9) 78 (22.2)
Thrombotic and embolic adverse
reactions, n (%)
54 (10.5) 36 (7.2) 12 (8.1) 12 (8.2) 42 (11.6) 24 (6.8)
Arterial 11 (2.1) 5 (1.0) 0 (0.0) 2 (1.4) 11 (3.0) 3 (0.9)
Myocardial infarctionb 5 (1.0) 1 (0.2) 0 (0.0) 1 (0.7) 5 (1.4) 0 (0.0)
Venous 27 (5.3) 18 (3.6) 10 (6.7) 7 (4.8) 17 (4.7) 11 (3.1)
Cerebrovascular disordersc, n (%) 19 (3.7) 21 (4.2) 2 (1.3) 8 (5.5) 17 (4.7) 13 (3.7)
Hypertension, n (%) 28 (5.5) 22 (4.4) 8 (5.4) 4 (2.7) 20 (5.5) 18 (5.1)
Cardiac failure, n (%) 14 (2.7) 14 (2.8) 6 (4.0) 1 (0.7) 8 (2.2) 13 (3.7)
Edema, n (%) 60 (11.7) 45 (9.1) 24 (16.1) 16 (11.0) 36 (9.9) 29 (8.3)
Respiratory, thoracic, and
mediastinal disorders, n (%)d
180 (35.2) 200 (40.2) 61 (40.9) 63 (43.2) 119 (32.8) 137 (39.0)
Dyspnea 73 (14.3) 96 (19.3) 26 (17.4) 39 (26.7) 47 (12.9) 57 (16.2)
Cough 66 (12.9) 77 (15.5) 20 (13.4) 19 (13.0) 46 (12.7) 58 (16.5)
Pulmonary embolisme 9 (1.8) 3 (0.6) 3 (2.0) 0 (0.0) 6 (1.7) 3 (0.9)
Pulmonary edemaf 2 (0.4) 5 (1.0) 1 (0.7) 1 (0.7) 1 (0.3) 4 (1.1)
NSCLC: non-small cell lung cancer and SCLC: small cell lung cancer.
a Adverse events were identiﬁed based on standard medical queries using MedDRA Version 12.1.
b Includes myocardial infarction and acute myocardial infarction.
c “Cerebrovascular disorders” encompasses central nervous system hemorrhages and cerebrovascular accidents (ischemic and hemorrhagic). Events in this category may
also  be included under “thrombotic and embolic adverse reactions.”
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.2%), with a higher percentage of venous events (DA, 5.3%; placebo,
.6%) and arterial events (DA, 2.1%; placebo, 1.0%). Cerebrovascular
isorders occurred in 3.7% of DA patients and in 4.2% of placebo
atients. Pulmonary edema and pulmonary embolism were infre-
uently reported (Table 3), but pulmonary edema was numerically
ore common in the placebo group, while pulmonary embolism
as more common in the DA group.
DA therapy, either as a single variable or in combination with
aseline factors, did not predict reduced survival in Cox propor-
ional hazards or multivariate modeling (Online Appendix text and
able A1).
. Discussion
In this analysis of controlled studies of ESA use in patients
ith lung cancer, ESA treatment produced a substantial reduction
n transfusion use but had no major effect on overall survival or
rogression-free survival. DA therapy was associated with a higher
ate of thrombotic and embolic adverse events, but other AEs were
enerally distributed similarly between DA recipients and controls.
Results of these analyses are consistent with ﬁndings reported
or patients with various tumor types, including the patient-level
eta-analysis by Ludwig et al. [45] and the study-level meta-
nalysis reported by Glaspy et al. [24]. The clinical beneﬁt of ESAs
or patients with SCLC or NSCLC was shown by reduced rates
f transfusion. In the patient-level analysis, the higher incidence
f transfusions for NSCLC patients compared with SCLC patients
Fig. 2C) may  have been associated with differences in entry crite-
ia for the Pirker study, which required baseline hemoglobin to be
9 g/dL and ≤13 g/dL at the initiation of DA [14], whereas other
tudies did not specify a minimum hemoglobin level; the SCLC
atients in the Pirker study represented a large proportion of the
CLC patients in the analysis. FACT-F score changes were similar
etween treatment groups in the overall lung cancer population
nd among SCLC patients, but NSCLC patients experienced a mean
.54-point improvement with DA and a mean 1.45-point decrease
ith placebo.st for this patient population).
tions.”
The EPO-CAN-20 [34] study added to the concerns about the use
of ESAs in patients with cancer receiving neither chemotherapy nor
radiotherapy; these concerns are reﬂected in current ESA labeling,
which does not recommend ESA use for treating cancer patients
who  are not receiving chemotherapy or radiotherapy. However,
these concerns do not readily apply to all lung cancer patients.
Patients in the EPO-CAN-20 study were not receiving chemother-
apy and the study was terminated after only 70 of the planned
300 patients were randomized. These differences were reﬂected in
the fact that the OR for death in the EPO-CAN-20 study was 2.82
(95% CI, 0.28–28.56) [34], whereas in the study-level analysis of
chemotherapy or radiochemotherapy studies reported here, the OR
was  0.87 (95% CI, 0.69–1.09). Another reason that the EPO-CAN-20
study is not directly applicable to all lung cancer patients is that
the etiology of anemia in patients not receiving chemotherapy or
radiotherapy is different from that of anemia in patients receiving
myelosuppressive chemotherapy [46].
The meta-analyses presented here have limitations. Studies
varied in design and reported endpoints; mortality and disease
progression were usually safety endpoints only, with inconsistent
criteria for disease progression. Various hemoglobin thresholds
were used as the basis for the start of ESA therapy, and studies
differed in their management of iron deﬁciency. While these fac-
tors could have affected mortality and disease progression, their
effects cannot be analyzed methodically because reporting was lim-
ited and inconsistent. Results of the patient-level analysis including
long-term follow-up were heavily weighted toward the results of
the Vansteenkiste and Pirker studies [14,15], since data from the
Kotasek study [43] were truncated when the optional cross-over
for patients randomized to placebo began (per the Cochrane anal-
ysis approach [41]), and the Hernandez study [42] did not have
a long-term follow-up period. A further limitation is the fact that
these studies reﬂect dosing guidelines in effect at the time they
were conducted, so the effects of current dosing recommendations
are unknown. In a 2011 review of meta-analyses of ESA use in
cancer patients, Bohlius et al. pointed out that a common short-
coming of meta-analyses is the restriction of data to published
reports, thereby exposing the analyses to the risk of publication
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ias; they recommend studies that incorporate individual patient
ata [47]. By including individual patient data from both published
nd unpublished sources, the meta-analysis study described here
voids some of these limitations. It is also possible that different
ethods (e.g., unweighted meta-analysis) would yield different
esults.
This meta-analysis makes important contributions to under-
tanding how ESA support affects patients with lung cancer. To our
nowledge, this is the ﬁrst meta-analysis of ESA use in patients
ith lung cancer, providing a systematic analysis of ESA use in
atients receiving chemotherapy for treatment of SCLC and NSCLC.
his study extends the available evidence regarding the beneﬁts
nd risks of ESA therapy, which may  assist clinicians in identifying
he most appropriate anemia therapy for their patients with lung
ancer.
. Conclusions
In this meta-analysis of controlled ESA studies conducted in
ung cancer patients, ESA treatment reduced the rate of transfu-
ion, with no effect on overall survival or progression-free survival.
SAs were generally well tolerated, although a patient-level meta-
nalysis indicated that the risk of thrombotic and embolic events
as higher for patients receiving DA compared with placebo (10.5%
s 7.2%). As transfusions are also associated with risks, ESA usage
hould be considered in patients with lung cancer receiving myelo-
uppressive chemotherapy.
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